Before the first seizure: The developmental imprint of infant epilepsy on neurodevelopment

M Milh1

  • 1Service de neurologie pédiatrique, Timone children hospital, Aix-Marseille université, AP-HM, 264, rue Saint Pierre, 13005 Marseille, France.

Revue Neurologique
|March 12, 2023
PubMed

Insights

Early-onset epilepsy in infants often leads to poor developmental outcomes, influenced by seizure onset, drug resistance, and etiology. Epilepsy is viewed as a neurodevelopmental disorder impacting development early on.

Area of Science:

  • Pediatric Neurology
  • Developmental Neuroscience
  • Epileptology

Background:

  • Epilepsy in infants is clinically and etiologically heterogeneous, complicating generalized developmental outcome predictions.
  • Early-onset epilepsy is generally associated with poor developmental prognosis, linked to factors like seizure onset age, drug resistance, treatment, and underlying causes.
  • Specific conditions like Dravet syndrome, KCNQ2-related epilepsy, and focal cortical dysplasia highlight the complex interplay between epilepsy and neurodevelopment.

Purpose of the Study:

  • To explore the relationship between epilepsy parameters and infant neurodevelopment.
  • To propose a conceptual model viewing epilepsy as a primary neurodevelopmental disorder.
  • To understand why early intervention for seizures may have limited developmental benefits.

Main Methods:

  • Review and synthesis of existing literature on infantile epilepsy and neurodevelopment.
  • Focus on specific epilepsy syndromes: Dravet syndrome, KCNQ2-related epilepsy, and focal cortical dysplasia.
  • Development of a conceptual model to explain the impact of epilepsy on development.

Main Results:

  • A generalized link between infantile epilepsy and development is difficult to establish due to heterogeneity.
  • Key parameters influencing developmental prognosis include age at first seizure, drug resistance, treatment, and etiology.
  • Epilepsy's severity on development is proposed to stem from its early 'imprint' on the developmental process.

Conclusions:

  • Epilepsy should be conceptualized as a neurodevelopmental disorder where the timing and nature of its impact on development are critical.
  • The precocity of epilepsy's developmental imprint suggests that treating seizures after onset may offer limited benefits for overall development.
  • Understanding epilepsy as a developmental disorder necessitates a shift in focus from symptom management to addressing the underlying developmental trajectory.

Related Concept Videos

Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
235
Seizures: Classification01:13

Seizures: Classification

Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
502
Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
2.6K
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
384